+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Plaque Psoriasis: Seven-Market Drug Forecast and Market Analysis - Update

  • PDF Icon

    Report

  • 115 Pages
  • September 2024
  • Region: Global
  • GlobalData
  • ID: 6007392

This publication is an update to the report Plaque Psoriasis: Global Drug Forecast and Market Analysis to 2030 which covered the forecast period 2020-30. This updated publication also covers the same forecast period.

The analyst estimated the value of the global PsO market to be $11.6 billion across the 7MM in 2020. By 2030, PsO sales across are expected to grow to $31.7 billion, representing a compound annual growth rate (CAGR) of 10.6% over the 10-year forecast period.

Major drivers of growth in the PsO market over the forecast period include:

  • Steady increase in total diagnosed prevalence across the 7MM
  • Launches of seven new pipeline agents: SAR44156, JNJ-2113, sonelokimab, DC-806, orismilast, Piclidenoson, and TAK-279.
  • Increased treatment options for mild and moderate patients, a historically undertreated population

The major barriers of growth in the PsO market during the forecast period include :

  • Loss of patent protection in the US of biologics, such as Janssen’s Stelara (ustekinumab) in 2024 and Cosentyx in 2029, and the subsequent launches of their corresponding biosimilars
  • Launch of apremilast generics in 2028 in the US
  • Passage of the Inflation Reduction Act (IRA) and other legislature in the US aimed to reduce drug prices.

Key Highlights

  • In 2022, The analyst estimated that the global HF market reached $31.9 billion across the 7MM, and expects the HF market to grow at a strong Compound Annual Growth Rate of 5.2%, reaching sales of $53 billion by 2032.

Major drivers of HF market growth over the forecast period are the :

  • Anticipated expanded indications for sodium-glucose co-transporter inhibitors.
  • Launch of several oral and injectable agents.
  • Increase in the global prevalence of chronic HF.

Scope

  • Overview of PsO, including epidemiology, symptoms, diagnosis, and disease management.
  • Annualized PsO therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2020 to 2030.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the PsO therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for PsO treatment. The most promising candidates in late-stage development are profiled.
  • Analysis of the current and future market competition in the global PsO therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the 7MM PsO therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM PsO therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Plaque Psoriasis: Executive Summary - Updated April 2024, Based on Events up to April 1, 2024
1.1 PsO market to experience conservative growth from 2020-30.
1.2 New players to enter a saturated field.
1.3 Opportunities remain for undertreated patient populations.
1.4 Innovator small molecules dominate the late-stage pipeline
1.5 What do physicians think?
2 Introduction
2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports
3 Disease Overview - Updated April 2024, Based on Events up to April 1, 2024
3.1 Etiology and pathophysiology
4 Epidemiology
4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 Forecast methodology.
4.5 Epidemiological forecast for PsO (2020-30)
4.6 Discussion
5 Disease Management - Updated April 2024, Based on Events up to April 1, 2024
5.1 Diagnosis
5.2 Treatment
6 Competitive Assessment - Updated April 2024, Based on Events up to April 1, 2024
6.1 Overview
6.2 Biosimilars
7 Unmet Needs and Opportunity Assessment - Updated April 2024, Based on Events up to April 1, 2024
7.1 Overview
7.2 Cost-effective therapies
7.3 Efficacious therapies for treatment refractory patients
7.4 Lack of innovative topical therapies
7.5 Treatment options for mild PsO patients
8 R&D Strategies - Updated April 2024, Based on Events up to April 1, 2024
8.1 Development shifts away from injectable biologics
8.2 New players enter the late-stage pipeline
8.3 Clinical trials design
9 Pipeline Assessment - Updated April 2024, Based on Events up to April 1, 2024
9.1 Overview
9.2 Promising drugs in clinical development
9.3 Other drugs of note
10 Pipeline Valuation Analysis - Updated April 2024, Based on Events up to April 1, 2024
10.1 Overview
10.2 Competitive assessment
11 Current and Future Players - Updated April 2024, Based on Events up to April 1, 2024
11.1 Overview
11.2 Deal-making trends
12 Market Outlook - Updated April 2024, Based on Events up to April 1, 2024
12.1 Global markets
12.2 US
12.3 5EU
12.4 Japan
13 Appendix
13.1 Abbreviations
13.2 Methodology
13.3 Primary Research - KOLs and payors interviewed for this report.
13.4 Bibliography
13.5 Primary research - prescriber survey
13.6 About the authors
13.7 Contact the Publisher
List of Tables
Table 1: Plaque psoriasis: key metrics in the 7MM
Table 2: Risk factors and comorbidities for PsO
Table 3: Classification of PsO by BSA
Table 4: Treatment guidelines for plaque psoriasis
Table 5: Top completed deals in PsO market by value, 2018-23
Table 6: PsO market - global drivers and barriers, 2020-30
Table 7: Key events impacting sales for PsO in the US, 2020-30
Table 8: PsO market - drivers and barriers in the US, 2020-30
Table 9: Key events impacting sales for PsO in the 5EU, 2020-30
Table 10: PsO market - drivers and barriers in the 5EU, 2020-30
Table 12: Key events impacting sales for PsO in Japan, 2020-30
Table 11: PsO market - drivers and barriers in Japan, 2020-30
Table 13: High-prescribing physicians (non-KOLs) surveyed, by country
List of Figures
Figure 1: Global sales forecast by country for PsO in 2020 and 2030
Figure 2: Analysis of the company portfolio gap in PsO during the forecast period
Figure 3: Competitive assessment of the pipeline/recently approved biologic drugs benchmarked against the SOC, Humira
Figure 4: Competitive assessment of the pipeline small molecule drugs benchmarked against the SOC, Otezla
Figure 5: Biologic and small molecule targets in the Treatment of PsO
Figure 6: 7MM, lifetime diagnosed prevalence of pediatric PsO (%), boys and girls, Ages =17 Years, 2020
Figure 7: 7MM, lifetime diagnosed prevalence of adult PsO (%), men and women, ages =18 years, 2020
Figure 8: Sources used for lifetime diagnosed prevalent cases of pediatric PsO
Figure 9: Sources used and not used for lifetime diagnosed prevalent cases of PsO in adults
Figure 10: Sources used for lifetime diagnosed prevalent cases of PsO by severity among adults
Figure 11: Sources used for lifetime diagnosed prevalent cases of PsO with PsA among adults
Figure 12: 7MM, lifetime diagnosed prevalent cases of PsO, men and women, all ages, 2020 (N)
Figure 13: Age-specific lifetime diagnosed prevalent cases of PsO, 7MM, men and women, 2020 (N)
Figure 14: 7MM, sex-specific lifetime diagnosed prevalent cases of PsO, all ages, 2020 (N)
Figure 15: 7MM, lifetime diagnosed prevalent cases of PsO by severity, men and women, =18 years, 2020
Figure 16: 7MM, lifetime diagnosed prevalent cases of PsO with psoriatic arthritis, men and women, =18 years, 2020 (N)
Figure 17: Overall treatment algorithm for PsO as approved by EMA
Figure 18: Unmet needs and opportunities in PsO
Figure 19: Overview of the development pipeline in PsO
Figure 20: Key late-stage trials for the promising pipeline agents that the analyst expects to be licensed for PsO in the 7MM during the forecast period
Figure 21: Competitive assessment of the pipeline/recently approved biologic drugs benchmarked against the SOC, Humira
Figure 22: Competitive assessment of the pipeline small molecules drugs benchmarked against the SOC, Otezla
Figure 23: Analysis of the company portfolio gap in PsO during the forecast period
Figure 24: Global (7MM) sales forecast by country for PsO in 2020 and 2030
Figure 25: Sales forecast by class for PsO in the US in 2020 and 2030
Figure 26: Sales forecast by class for PsO in the 5EU in 2020 and 2030
Figure 27: Sales forecast by class for PsO in Japan in 2020 and 2030